ALXO - CIK 0001810182
ALX ONCOLOGY HOLDINGS INC (ALXO) reported net income of -$101.69M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$101.69M | +24.6% |
| FY 2024 | -$134.85M | +16.1% |
| FY 2023 | -$160.81M | -30.2% |
| FY 2022 | -$123.48M | -47.9% |
| FY 2021 | -$83.46M | -82.5% |
| FY 2020 | -$45.74M | -137.7% |
| FY 2019 | -$19.24M | -40.1% |
| FY 2018 | -$13.73M | - |
ALX ONCOLOGY HOLDINGS INC (ALXO) reported net income of -$101.69M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2018 and fiscal 2025, ALX ONCOLOGY HOLDINGS INC's net income declined from -$13.73M to -$101.69M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.